Early IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target
Alberto Potenzieri,Sara Uccella,Deborah Preiti,Matteo Pisoni,Silvia Rosati,Chiara Lavarello,Martina Bartolucci,Doriana Debellis,Federico Catalano,Andrea Petretto,Lino Nobili,Tommaso Fellin,Valter Tucci,Luca A. Ramenghi,Annalisa Savardi,Laura Cancedda
DOI: https://doi.org/10.1126/sciadv.adk8123
IF: 13.6
2024-03-02
Science Advances
Abstract:Besides recent advances in neonatal care, preterm newborns still develop sex-biased behavioral alterations. Preterms fail to receive placental insulin-like growth factor-1 (IGF-1), a major fetal growth hormone in utero, and low IGF-1 serum levels correlate with preterm poor neurodevelopmental outcomes. Here, we mimicked IGF-1 deficiency of preterm newborns in mice by perinatal administration of an IGF-1 receptor antagonist. This resulted in sex-biased brain microstructural, functional, and behavioral alterations, resembling those of ex-preterm children, which we characterized performing parallel mouse/human behavioral tests. Pharmacological enhancement of GABAergic tonic inhibition by the U.S. Food and Drug Administration–approved drug ganaxolone rescued functional/behavioral alterations in mice. Establishing an unprecedented mouse model of prematurity, our work dissects the mechanisms at the core of abnormal behaviors and identifies a readily translatable therapeutic strategy for preterm brain disorders.
multidisciplinary sciences